View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 7, 2019

BRAINBox gets breakthrough status for concussion diagnosis test

BRAINBox Solutions has received breakthrough device designation from the US Food and Drug Administration (FDA) for a test intended to help in diagnosis and prognosis of mild traumatic brain injury (TBI) or concussion.

BRAIN Box Solutions has received breakthrough device designation from the US F ood and Drug Administration (F DA) for a test intended to help in diagnosis and prognosis of mild traumatic brain injury (TBI) or concussion.

N amed BRAIN Box TBI, the quantitative test leverages injury-related blood protein biomarkers along with computerised neurological assessments.

It comprises a multiplex, fluorescence immunoassay with an in-vitro diagnostic serum measurements panel that includes the Glial F ibrillary Acidic Protein (GF AP), N euron Specific Enolase (N SE) and N eurogranin (N RGN ) biomarkers among others.

Results derived from these measurements will be quantitatively interpreted in conjunction with the computerised neurological assessments.

BRAIN Box TBI is designed to offer a single score with data from all the test components as well as additional data that could guide treatment decisions.

The test is meant for both point-of-care and clinical laboratory use in patients aged 18 years and above treated at a hospital emergency department or urgent care centre.

BRAIN Box Solutions president and CEO Donna Edmonds said: “With more than five million patients in the US each year evaluated for mild TBI in hospital emergency departments, there is an enormous need for better tools to objectively diagnose and manage this condition.

“The breakthrough designation underscores the potential of BrainBox TBI to change clinical practice in concussion management and will accelerate our development programme.”

“The breakthrough designation underscores the potential of BrainBox TBI to change clinical practice in concussion management.”

The company commenced the HeadSMART II clinical study of BRAIN Box TBI to support regulatory filings for marketing approval in the US as well as international markets.

During the study, serial assessments will be collected across 20 sites in the US, UK and Australia over approximately 18-20 months. It will recruit patients in hospital emergency rooms and urgent care centre settings.

The study is designed to gather cognitive and neuropsychological test data required to analyse a patient’s cognitive state, along with the biologic response measured by biomarkers released upon injury.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network